Rhode Island House Bill H7187

Rhode Island 2026 Regular Session

• Introduced: 1/21/26
• Refer: 1/21/26

Caption

Prohibits healthcare insurers from requiring or conducting a review for prescription medicine used to treat alcohol or opioid use disorder containing Methadone, Burenorphine, or Naltrexone, or approved to mitigate opioid withdrawal symptoms.

Impact

The implications of H7187 are significant, particularly for individuals receiving treatment for alcohol or opioid use disorders. It explicitly forbids any prospective or concurrent review by insurers for specific medications used in these treatments, including Methadone, Buprenorphine, or Naltrexone. This legislative measure seeks to simplify access to crucial medications for addiction treatment, thus promoting better health outcomes for patients and potentially reducing the burden on healthcare systems faced with opioid-related issues.

Summary

House Bill H7187 aims to amend the existing Benefit Determination and Utilization Review Act by prohibiting healthcare insurers from conducting retrospective utilization reviews for prescription medications if prior approval has been obtained. This is intended to protect patients from coverage denials after they have received necessary medical treatments, ensuring that care is not jeopardized due to administrative processes unless issues of fraud or substantial misrepresentation exist. The bill's effective date is set to commence on January 1, 2027, for relevant health benefit plans.

Contention

While supporters advocate for the bill as a necessary step for patient rights and public health, concerns may arise regarding the administrative effectiveness and financial impact on insurers. Critics may argue that the lack of utilization review could lead to inappropriate prescribing practices if not monitored, ultimately affecting healthcare costs and outcomes. Balancing patient access to necessary treatments while ensuring responsible prescribing is likely to be a significant point of contention as the bill progresses through the legislative process.